Research Paper Volume 15, Issue 24 pp 14996—15024
ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network
Figure 10. Correlation between ATRX expression, TILs level and survival outcomes of patients with HER2-/HR+ BC on the TMA. (A) Correlation between ATRX and OS, DFS in patients with HER2-/HR+ BC who received endocrinotherapy or did not receive endocrinotherapy. (B) Correlation between ATRX and OS, DFS in patients with HER2-/HR+ BC who received chemotherapy or did not receive chemotherapy. (C) Correlation between ATRX combined with TILs and OS, DFS in patients with HER2-/HR+ BC who received endocrinotherapy or did not receive endocrinotherapy. (D) Correlation between ATRX combined with TILs and OS, DFS in patients with HER2-/HR+ BC who received chemotherapy or did not receive chemotherapy. ATRX(H): ATRX-High expression group, ATRX(L): ATRX-Low expression group, Opposite: the group with ATRX expression tendency opposited to TILs, both H: both ATRX- and TILs-High group, both L: both ATRX- and TILs-Low group.